XML 60 R50.htm IDEA: XBRL DOCUMENT
v3.23.3

Investment in Cornerstone Pharmaceuticals (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions |  |  |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | --- | --- | ---
Jul. 31, 2022 | Jun. 17, 2022 | Oct. 01, 2021 | Sep. 24, 2021 | Oct. 31, 2023
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Principal amount (in Dollars) |  |  |  |  | $ 44.0
Ownership percentage in non-operating subsidiary |  |  |  |  | 50.00%
Ownership interest percentage |  |  |  |  | 8.00%
CS Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Indirect interest in assets held, percentage |  |  |  |  | 45.00%
Rafael Pharmaceuticals [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Percentage of outstanding capital stock |  |  |  |  | 51.00%
Percentage of outstanding capital stock on fully diluted basis |  |  |  |  | 42.00%
Fully diluted |  |  |  |  | 10.00%
Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Ownership percentage in non-operating subsidiary |  |  |  |  | 90.00%
Ownership interest percentage |  |  |  |  | 51.00%
Aggregate amount (in Dollars) |  |  |  | $ 25.0 |
Agreement accrues interest per annum |  | 9.00% |  |  |
Reserve amount (in Dollars) | $ 25.0 |  |  |  |
Series D Convertible Preferred Stock [Member] | CS Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Purchase of exercise the warrant, shares (in Shares) |  |  |  |  | 16.7
Series D Preferred Stock [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Convertible preferred stock per share (in Dollars per share) |  |  |  |  | $ 1.25
Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Owned non-operating subsidiary |  |  |  |  | 90.00%
CS Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Owned non-operating subsidiary |  |  |  |  | 50.00%
Howard Jonas [Member] | Rafael Pharmaceuticals [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Fully diluted |  |  |  |  | 10.00%
Howard Jonas [Member] | Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Owned non-operating subsidiary |  |  |  |  | 10.00%
First Advance [Member] | Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Advance amount of debtor (in Dollars) |  |  |  | $ 1.9 |
Second Advance [Member] | Pharma Holdings, LLC [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Advance amount of debtor (in Dollars) |  |  | $ 23.1 |  |
Subsidiary Pharma Holdings [Member] |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |
Held percentage |  |  |  |  | 43.00%

X
- Definition Fully diluted. + References No definition available. + Details
Name: | rfl_FullyDiluted
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | rfl_IndirectInterestAssetsPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rfl_InvestmentinCornerstonePharmaceuticalsDetailsLineItems
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ownership interest percentage. + References No definition available. + Details
Name: | rfl_OwnershipInterestPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary. + References No definition available. + Details
Name: | rfl_PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of outstanding capital stock. + References No definition available. + Details
Name: | rfl_PercentageOfOutstandingCapitalStock
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of outstanding capital stock on fully diluted basis. + References No definition available. + Details
Name: | rfl_PercentageOfOutstandingCapitalStockOnFullyDilutedBasis
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares purchase of exercise the warrant. + References No definition available. + Details
Name: | rfl_PurchaseOfExerciseWarrantShares
Namespace Prefix: | rfl_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The average effective interest rate during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentInterestRateDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense (income) related to reorganization items classified as other. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481435/852-10-45-9 + Details
Name: | us-gaap_DebtorReorganizationItemsOtherExpenseIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2 + Details
Name: | us-gaap_IncomeTaxHolidayAggregateDollarAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase in allowance for credit loss on security purchased under agreement to resell, from recovery. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRecovery
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_OwnershipAxis=rfl_CSPharmaHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=rfl_RafaelPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=rfl_PharmaHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=rfl_SeriesDConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_PharmaHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rfl_CSPharmaHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=rfl_HowardJonasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=rfl_FirstAdvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=rfl_SecondAdvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rfl_SubsidiaryPharmaHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |